632 related articles for article (PubMed ID: 22469616)
1. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
2. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
3. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
4. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
5. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
[TBL] [Abstract][Full Text] [Related]
6. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.
Jara-Acevedo M; Teodosio C; Sanchez-Muñoz L; Álvarez-Twose I; Mayado A; Caldas C; Matito A; Morgado JM; Muñoz-González JI; Escribano L; Garcia-Montero AC; Orfao A
Mod Pathol; 2015 Aug; 28(8):1138-49. PubMed ID: 26067933
[TBL] [Abstract][Full Text] [Related]
7. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
[TBL] [Abstract][Full Text] [Related]
8. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
9. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
10. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.
Broesby-Olsen S; Kristensen T; Vestergaard H; Brixen K; Møller MB; Bindslev-Jensen C;
J Allergy Clin Immunol; 2013 Sep; 132(3):723-728. PubMed ID: 23587333
[TBL] [Abstract][Full Text] [Related]
11. Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis.
Grootens J; Ungerstedt JS; Ekoff M; Rönnberg E; Klimkowska M; Amini RM; Arock M; Söderlund S; Mattsson M; Nilsson G; Dahlin JS
EBioMedicine; 2019 May; 43():150-158. PubMed ID: 30975542
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
[TBL] [Abstract][Full Text] [Related]
13. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
[TBL] [Abstract][Full Text] [Related]
14. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
15. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
[TBL] [Abstract][Full Text] [Related]
16. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).
Sotlar K; Colak S; Bache A; Berezowska S; Krokowski M; Bültmann B; Valent P; Horny HP
J Pathol; 2010 Apr; 220(5):586-95. PubMed ID: 20112369
[TBL] [Abstract][Full Text] [Related]
17. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.
Morgado JM; Perbellini O; Johnson RC; Teodósio C; Matito A; Álvarez-Twose I; Bonadonna P; Zamò A; Jara-Acevedo M; Mayado A; Garcia-Montero A; Mollejo M; George TI; Zanotti R; Orfao A; Escribano L; Sánchez-Muñoz L
Histopathology; 2013 Dec; 63(6):780-7. PubMed ID: 24111625
[TBL] [Abstract][Full Text] [Related]
18. KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB
Dermatology; 2013; 226(3):233-7. PubMed ID: 23774045
[TBL] [Abstract][Full Text] [Related]
19. Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders.
Perbellini O; Zamò A; Colarossi S; Zampieri F; Zoppi F; Bonadonna P; Schena D; Artuso A; Martinelli G; Chilosi M; Pizzolo G; Zanotti R
Cytometry B Clin Cytom; 2011 Nov; 80(6):362-8. PubMed ID: 21656905
[TBL] [Abstract][Full Text] [Related]
20. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia.
Nagai S; Ichikawa M; Takahashi T; Sato H; Yokota H; Oshima K; Izutsu K; Hangaishi A; Kanda Y; Motokura T; Chiba S; Yatomi Y; Kurokawa M
Exp Hematol; 2007 Nov; 35(11):1747-52. PubMed ID: 17976525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
